158 related articles for article (PubMed ID: 30581498)
1. Predictive Value of Two Polymorphisms of ERCC2, rs13181 and rs1799793, in Clinical Outcomes of Chemotherapy in Gastric Cancer Patients: A Meta-Analysis.
Li M; Zhao Y; Zhao E; Wang K; Lu W; Yuan L
Dis Markers; 2018; 2018():3947626. PubMed ID: 30581498
[TBL] [Abstract][Full Text] [Related]
2. Influences of ERCC1, ERCC2, XRCC1, GSTP1, GSTT1, and MTHFR polymorphisms on clinical outcomes in gastric cancer patients treated with EOF chemotherapy.
Liu R; Zhao X; Liu X; Chen Z; Qiu L; Geng R; Guo W; He G; Yin J; Li J; Zhu X
Tumour Biol; 2016 Feb; 37(2):1753-62. PubMed ID: 26314858
[TBL] [Abstract][Full Text] [Related]
3. ERCC1 and ERCC2 variants predict survival in gastric cancer patients.
Li Y; Liu Z; Liu H; Wang LE; Tan D; Ajani JA; Wei QY
PLoS One; 2013; 8(9):e71994. PubMed ID: 24023723
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of ERCC1 and ERCC2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapy.
Mo J; Luo M; Cui J; Zhou S
Int J Clin Exp Pathol; 2015; 8(11):15065-71. PubMed ID: 26823845
[TBL] [Abstract][Full Text] [Related]
5. Genetic variability of ERCC1 and ERCC2 influences treatment outcomes in gastric cancer.
Yu WH; Wang YX; Guo JQ; Wang YL; Zheng JS; Zhu KX
Genet Mol Res; 2015 Dec; 14(4):17529-35. PubMed ID: 26782397
[TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphisms of DNA repair pathways influence the response to chemotherapy and overall survival of gastric cancer.
Zhou J; Liu ZY; Li CB; Gao S; Ding LH; Wu XL; Wang ZY
Tumour Biol; 2015 Apr; 36(4):3017-23. PubMed ID: 25542228
[TBL] [Abstract][Full Text] [Related]
7. Genetic variability of genes in NER pathway influences the treatment outcome of gastric cancer.
Xue MH; Li GY; Wu XJ; Zhang CX; Zhang CF; Zhu KX
Int J Clin Exp Pathol; 2015; 8(5):5563-9. PubMed ID: 26191265
[TBL] [Abstract][Full Text] [Related]
8. Genetic polymorphisms in ERCC1 and ERCC2 genes are associated with response to chemotherapy in osteosarcoma patients among Chinese population: a meta-analysis.
Zhang H; Ge J; Hong H; Bi L; Sun Z
World J Surg Oncol; 2017 Apr; 15(1):75. PubMed ID: 28388903
[TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphisms in DNA repair genes and their association with risk of cervical cancer: A systematic review and meta-analysis.
Shao X; Yang X; Liu Y; Song Q; Pan X; Chen W; Jiang W; Xu D; Song Y; Chen R
J Obstet Gynaecol Res; 2022 Sep; 48(9):2405-2418. PubMed ID: 35732591
[TBL] [Abstract][Full Text] [Related]
10. Association between common polymorphisms in ERCC gene and glioma risk: A meta-analysis of 15 studies.
Qian T; Zhang B; Qian C; He Y; Li Y
Medicine (Baltimore); 2017 May; 96(20):e6832. PubMed ID: 28514298
[TBL] [Abstract][Full Text] [Related]
11. Genetic variability of ERCC1 and ERCC2 genes involved in the nucleotide excision repair pathway influences the treatment outcome of gastric cancer.
Zheng DL; Tang GD; Chen YN; Zhang T; Qin MB
Genet Mol Res; 2016 Apr; 15(2):. PubMed ID: 27173253
[TBL] [Abstract][Full Text] [Related]
12. XPD Polymorphisms and Risk of Hepatocellular Carcinoma and Gastric Cancer: A Meta-Analysis.
Zhou Q; Fu Y; Wen L; Deng Y; Chen J; Liu K
Technol Cancer Res Treat; 2021; 20():1533033821990046. PubMed ID: 33517857
[TBL] [Abstract][Full Text] [Related]
13. A genetic variant in ERCC2 is associated with gastric cancer prognosis in a Chinese population.
Chu H; Gu D; Xu M; Xu Z; Gong Y; Gong W; Tang Y; Zhou J; Tong N; Zhang Z; Chen J; Wang M
Mutagenesis; 2013 Jul; 28(4):441-6. PubMed ID: 23680703
[TBL] [Abstract][Full Text] [Related]
14. ERCC2 Lys751Gln and Asp312Asn polymorphisms and gastric cancer risk: a meta-analysis.
Chen B; Zhou Y; Yang P; Wu XT
J Cancer Res Clin Oncol; 2011 Jun; 137(6):939-46. PubMed ID: 20981556
[TBL] [Abstract][Full Text] [Related]
15. Association between polymorphisms in ERCC2 gene and oral cancer risk: evidence from a meta-analysis.
Zhang E; Cui Z; Xu Z; Duan W; Huang S; Tan X; Yin Z; Sun C; Lu L
BMC Cancer; 2013 Dec; 13():594. PubMed ID: 24330540
[TBL] [Abstract][Full Text] [Related]
16. XRCC1 and XPD genetic polymorphisms and clinical outcomes of gastric cancer patients treated with oxaliplatin-based chemotherapy: a meta-analysis.
Zhang X; Jiang LP; Yin Y; Wang YD
Tumour Biol; 2014 Jun; 35(6):5637-45. PubMed ID: 24590266
[TBL] [Abstract][Full Text] [Related]
17. ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis.
Yin M; Yan J; Martinez-Balibrea E; Graziano F; Lenz HJ; Kim HJ; Robert J; Im SA; Wang WS; Etienne-Grimaldi MC; Wei Q
Clin Cancer Res; 2011 Mar; 17(6):1632-40. PubMed ID: 21278243
[TBL] [Abstract][Full Text] [Related]
18. Haplotype analysis on relationship of ERCC2 and ERCC3 gene polymorphisms with osteosarcoma risk in Chinese young population.
Xu Q; Zhang Z; Sun W; Hu B
Mamm Genome; 2017 Jun; 28(5-6):227-233. PubMed ID: 28474168
[TBL] [Abstract][Full Text] [Related]
19. Effect of
Zhang H; Li Y; Guo S; Wang Y; Wang H; Lu D; Wang J; Jin L; Jiang G; Wu J; Han Y; Li J
Am J Transl Res; 2020; 12(10):6941-6953. PubMed ID: 33194084
[TBL] [Abstract][Full Text] [Related]
20. Significant association between ERCC2 and MTHR polymorphisms and breast cancer susceptibility in Moroccan population: genotype and haplotype analysis in a case-control study.
Hardi H; Melki R; Boughaleb Z; El Harroudi T; Aissaoui S; Boukhatem N
BMC Cancer; 2018 Mar; 18(1):292. PubMed ID: 29544444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
